{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:04:58Z","timestamp":1780499098746,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Natural Science Foundation of Jiangsu Province","award":["BK20231158"],"award-info":[{"award-number":["BK20231158"]}]},{"name":"Medical research project of Jiangsu Provincial Health Commission","award":["M2022118"],"award-info":[{"award-number":["M2022118"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-025-03342-5","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:30:20Z","timestamp":1737703820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaoyu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3342_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570\u201381.","journal-title":"N Engl J Med"},{"key":"3342_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German neurological society. J Neurol. 2016;263:1473\u201394.","journal-title":"J Neurol"},{"key":"3342_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","volume":"23","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Utsugisawa K. Biological therapies for myasthenia gravis. Expert Opin Biol Ther. 2023;23:253\u201360.","journal-title":"Expert Opin Biol Ther"},{"key":"3342_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113\u201324.","journal-title":"Nat Rev Neurol"},{"key":"3342_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, H\u00e5kansson I, Johansson R, Jons D, Kmezic I, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79:1105\u201312.","journal-title":"JAMA Neurol"},{"key":"3342_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mus.26876","volume":"62","author":"SK Sahai","year":"2020","unstructured":"Sahai SK, Maghzi AH, Lewis RA. Rituximab in late-onset myasthenia gravis is safe and effective. Muscle Nerve. 2020;62:377\u201380.","journal-title":"Muscle Nerve"},{"key":"3342_CR7","doi-asserted-by":"crossref","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98:e376-e389.","DOI":"10.1212\/WNL.0000000000013121"},{"key":"3342_CR8","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","volume":"27","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos A, Noury JB, Genestet S, Nadaj-Pakleza A, Cassereau J, Baron C, Videt D, Michel L, Pereon Y, Wiertlewski S, et al. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol. 2020;27:2277\u201385.","journal-title":"Eur J Neurol"},{"key":"3342_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77:974\u201381.","journal-title":"JAMA Neurol"},{"key":"3342_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","volume":"18","author":"C Ruetsch-Chelli","year":"2021","unstructured":"Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M, Brglez V, Ticchioni M, Lebrun-Frenay C. Memory B cells predict relapse in rituximab-treated myasthenia gravis. Neurotherapeutics. 2021;18:938\u201348.","journal-title":"Neurotherapeutics"},{"key":"3342_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ram\u00edrez-Valle","year":"2024","unstructured":"Ram\u00edrez-Valle F, Maranville JC, Roy S, Plenge RM. Sequential immunotherapy: towards cures for autoimmunity. Nat Rev Drug Discov. 2024;23:501\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"3342_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103133","volume":"142","author":"A Merino-Vico","year":"2024","unstructured":"Merino-Vico A, van Hamburg JP, Tuijnenburg P, Frazzei G, Al-Soudi A, Bonasia CG, Helder B, Rutgers A, Abdulahad WH, Stegeman CA, et al. Targeting NF-\u03baB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis. J Autoimmun. 2024;142: 103133.","journal-title":"J Autoimmun"},{"key":"3342_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41467-017-02672-0","volume":"9","author":"HD Brightbill","year":"2018","unstructured":"Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, et al. NF-\u03baB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018;9:179.","journal-title":"Nat Commun"},{"key":"3342_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320421121","volume":"121","author":"MY Li","year":"2024","unstructured":"Li MY, Chong LC, Duns G, Lytle A, Woolcock B, Jiang A, Telenius A, Ben-Neriah S, Nawaz W, Slack GW, et al. TRAF3 loss-of-function reveals the noncanonical NF-\u03baB pathway as a therapeutic target in diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2024;121: e2320421121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3342_CR15","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.3324\/haematol.2021.279800","volume":"107","author":"S Decombis","year":"2022","unstructured":"Decombis S, Papin A, Bellanger C, Sortais C, Dousset C, Le Bris Y, Riveron T, Blandin S, Hulin P, Tessoulin B, et al. The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition. Haematologica. 2022;107:2905\u201317.","journal-title":"Haematologica"},{"key":"3342_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4049\/jimmunol.1401514","volume":"195","author":"HD Brightbill","year":"2015","unstructured":"Brightbill HD, Jackman JK, Suto E, Kennedy H, Jones C 3rd, Chalasani S, Lin Z, Tam L, Roose-Girma M, Balazs M, et al. Conditional deletion of NF-\u03baB-inducing kinase (NIK) in adult mice disrupts mature B cell survival and activation. J Immunol. 2015;195:953\u201364.","journal-title":"J Immunol"},{"key":"3342_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/eji.201546081","volume":"46","author":"M Hahn","year":"2016","unstructured":"Hahn M, Macht A, Waisman A, H\u00f6velmeyer N. NF-\u03baB-inducing kinase is essential for B-cell maintenance in mice. Eur J Immunol. 2016;46:732\u201341.","journal-title":"Eur J Immunol"},{"key":"3342_CR18","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1038\/ncomms6360","volume":"5","author":"KL Willmann","year":"2014","unstructured":"Willmann KL, Klaver S, Do\u011fu F, Santos-Valente E, Garncarz W, Bilic I, Mace E, Salzer E, Conde CD, Sic H, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360.","journal-title":"Nat Commun"},{"key":"3342_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419\u201325.","journal-title":"Neurology"},{"key":"3342_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.16047","volume":"168","author":"X Huang","year":"2024","unstructured":"Huang X, An X, Gao X, Wang N, Liu J, Zhang Y, Qi G, Zhang C. Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients. J Neurochem. 2024;168:224\u201337.","journal-title":"J Neurochem"},{"issue":"1","key":"3342_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13075-020-02372-z","volume":"23","author":"J Marken","year":"2021","unstructured":"Marken J, Muralidharan S, Giltiay NV. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021;23(1):5.","journal-title":"Arthritis Res Ther"},{"key":"3342_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-019-1687-x","volume":"16","author":"CL Yang","year":"2019","unstructured":"Yang CL, Zhang P, Liu RT, Zhang N, Zhang M, Li H, Du T, Li XL, Dou YC, Duan RS. CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells. J Neuroinflamm. 2019;16:282.","journal-title":"J Neuroinflamm"},{"key":"3342_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12:259\u201368.","journal-title":"Nat Rev Neurol"},{"key":"3342_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115872","volume":"218","author":"X Chen","year":"2023","unstructured":"Chen X, Qiu J, Gao Z, Liu B, Zhang C, Yu W, Yang J, Shen Y, Qi L, Yao X, et al. Myasthenia gravis: molecular mechanisms and promising therapeutic strategies. Biochem Pharmacol. 2023;218: 115872.","journal-title":"Biochem Pharmacol"},{"key":"3342_CR25","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.3390\/ijms21228470","volume":"21","author":"KM Pflug","year":"2020","unstructured":"Pflug KM, Sitcheran R. Targeting NF-\u03baB-inducing kinase (NIK) in immunity, inflammation, and cancer. Int J Mol Sci. 2020;21:8470.","journal-title":"Int J Mol Sci"},{"key":"3342_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930986","volume":"13","author":"MV Haselager","year":"2022","unstructured":"Haselager MV, Eldering E. The therapeutic potential of targeting NIK in B cell malignancies. Front Immunol. 2022;13: 930986.","journal-title":"Front Immunol"},{"key":"3342_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaut.2018.07.017","volume":"94","author":"SM Lacher","year":"2018","unstructured":"Lacher SM, Thurm C, Distler U, Mohebiany AN, Israel N, Kitic M, Ebering A, Tang Y, Klein M, Wabnitz GH, et al. NF-\u03baB inducing kinase (NIK) is an essential post-transcriptional regulator of T-cell activation affecting F-actin dynamics and TCR signaling. J Autoimmun. 2018;94:110\u201321.","journal-title":"J Autoimmun"},{"key":"3342_CR28","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.str.2012.09.012","volume":"20","author":"Z Tao","year":"2012","unstructured":"Tao Z, Ghosh G. Understanding NIK regulation from its structure. Structure. 2012;20:1615\u20137.","journal-title":"Structure"},{"key":"3342_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","volume":"20","author":"AA Zarrin","year":"2021","unstructured":"Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 2021;20:39\u201363.","journal-title":"Nat Rev Drug Discov"},{"key":"3342_CR30","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1172\/JCI23763","volume":"115","author":"K Aya","year":"2005","unstructured":"Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest. 2005;115:1848\u201354.","journal-title":"J Clin Invest"},{"key":"3342_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.655887","volume":"12","author":"VQ Nguyen","year":"2021","unstructured":"Nguyen VQ, Eden K, Morrison HA, Sammons MB, Knight KK, Sorrentino S, Brock RM, Grider DJ, Allen IC, Sorrentino D. Noncanonical NF-\u03baB signaling upregulation in inflammatory bowel disease patients is associated with loss of response to anti-TNF agents. Front Pharmacol. 2021;12: 655887.","journal-title":"Front Pharmacol"},{"key":"3342_CR32","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1182\/blood-2008-12-192914","volume":"113","author":"W Jin","year":"2009","unstructured":"Jin W, Zhou XF, Yu J, Cheng X, Sun SC. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood. 2009;113:6603\u201310.","journal-title":"Blood"},{"key":"3342_CR33","doi-asserted-by":"publisher","first-page":"ftaa045","DOI":"10.1093\/femspd\/ftaa045","volume":"78","author":"J Wang","year":"2020","unstructured":"Wang J, Wang B, Lv X, Wang L. NIK inhibitor impairs chronic periodontitis via suppressing non-canonical NF-\u03baB and osteoclastogenesis. Pathog Dis. 2020;78:ftaa045.","journal-title":"Pathog Dis"},{"key":"3342_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1096\/fj.201600840R","volume":"31","author":"X Ren","year":"2017","unstructured":"Ren X, Li X, Jia L, Chen D, Hou H, Rui L, Zhao Y, Chen Z. A small-molecule inhibitor of NF-\u03baB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury. FASEB J. 2017;31:711\u20138.","journal-title":"FASEB J"},{"key":"3342_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.149124","volume":"1843","author":"M Cao","year":"2024","unstructured":"Cao M, Yi L, Xu Y, Tian Y, Li Z, Bi Y, Guo M, Li Y, Liu Y, Xu X, et al. Inhibiting NF-\u03baB inducing kinase improved the motor performance of ALS animal model. Brain Res. 2024;1843: 149124.","journal-title":"Brain Res"},{"key":"3342_CR36","doi-asserted-by":"publisher","first-page":"22115","DOI":"10.1038\/srep22115","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Wang H, Zhou X, Xie X, Chen X, Jie Z, Zou Q, Hu H, Zhu L, Cheng X, et al. Cell intrinsic role of NF-\u03baB-inducing kinase in regulating T cell-mediated immune and autoimmune responses. Sci Rep. 2016;6:22115.","journal-title":"Sci Rep"},{"key":"3342_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954936","volume":"13","author":"I Rastogi","year":"2022","unstructured":"Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. Role of B cells as antigen presenting cells. Front Immunol. 2022;13: 954936.","journal-title":"Front Immunol"},{"key":"3342_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108180","volume":"238","author":"TX Chen","year":"2022","unstructured":"Chen TX, Fan YT, Peng BW. Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease. Pharmacol Ther. 2022;238: 108180.","journal-title":"Pharmacol Ther"},{"key":"3342_CR39","doi-asserted-by":"publisher","first-page":"1397916","DOI":"10.3389\/fimmu.2024.1397916","volume":"15","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Han X, Bi Z, Yang M, Lin J, Li Z, Zhang M, Bu B. Exhausted signature and regulatory network of NK cells in myasthenia gravis. Front Immunol. 2024;15:1397916.","journal-title":"Front Immunol"},{"issue":"1","key":"3342_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann NY Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann NY Acad Sci"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03342-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:30:30Z","timestamp":1737703830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-025-03342-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3342"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03342-5","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Affiliated Hospital of Xuzhou Medical University granted approval for this study (XYFY2023-KL471-01), and all participants provided written informed consent. All the animal experimental protocols were approved by the Ethics Committee of Xuzhou Medical University (202410T016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}